COPD trials in Italy
37 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 10 November 2026. Ask the study team whether a trial fits you.
- No phaseTaking peopleStudy on Impact of Maximal Strength Training in Patients With COPD
- Where
- Lumezzane
- Age
- 50 years to 80 years
- People
- 20
- Run by
- Istituti Clinici Scientifici Maugeri SpA
See details and how to joinNCT03799354 - Phase 2Not yet taking people in ItalyThe MAB Trial: A Study of Tozorakimab to Reduce Lung Inflammation and Promote Lung Healing in People with COPD.
- Where
- Milan
- Age
- 18 years and over
- People
- 60 worldwide
- Run by
- University Of Leicester
See details and how to join2025-522359-24-00 · EU 2025-522359-24-00 - Phase 2Taking peopleA Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
- Where
- Busto Arsizio, Cuneo, Ferrara, Milan, Monza, Naples, Pavia, Roma, Statte, Telese Terme
- Age
- 40 years and over
- People
- 987 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07082738 - Phase 2/3Taking peopleA Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease
- Where
- Bergamo, Catania, Ferrara, Milan, Naples, Reggio Emilia, Rome
- Age
- 35 years to 80 years
- People
- 1,156 worldwide
- Run by
- Pfizer
See details and how to joinNCT07363694 · EU 2024-518587-12-00 - Phase 4Taking peopleA Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.
- Where
- Cona, Giugliano in Campania, Orbassano, Siena
- Age
- 40 years to 85 years
- People
- 218 worldwide
- Run by
- Sanofi
See details and how to joinNCT07053423 - Phase 3Taking peopleEfficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
- Where
- Cona, Milan, Padova, Pavia, Reggio Emilia, Rozzano, Telese Terme, Tradate (Va)
- Age
- 40 years to 80 years
- People
- 942 worldwide
- Run by
- Sanofi
See details and how to joinNCT07190209 · EU 2024-518016-39-00 - Phase 4Taking peopleThis After Market Study is Seeing if Dupilumab Plus Usual Standard of Care (SOC) is Better Than Usual Care Alone for Adult Participants After a Severe Chronic Obstructive Pulmonary Disease (COPD) Flare-Up Requiring Hospitalization
- Where
- Ferrara, Genoa, Rozzano
- Age
- 40 years and over
- People
- 754 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT07587658 · EU 2025-524392-23-00 - Phase 2Not yet taking people in ItalyA Randomized, Double-Blind, Placebo-controlled, Parallel Arm, 52-week Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of Two Doses of EXPD-101 in Participants with COPD
- Where
- Bologna, Ferrara, Milan, Pisa
- Age
- 18 years and over
- People
- 183 worldwide
- Run by
- Expedition Therapeutics Inc.
See details and how to join2026-525216-34-00 · EU 2026-525216-34-00 - Phase 3Taking peopleDepemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
- Where
- Bari, Catania, Ferrara, Foggia, Genoa, Rome, Rozzano, Telese Terme
- Age
- 40 years to 80 years
- People
- 961 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT06961214 · EU 2024-520417-41-00 - Phase 3Taking peopleA Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
- Where
- Ancona, Florence, Genoa, Mestre (VE), Milan, Modena, Naples, Pavia, Perugia, Rome, Siena, Varese
- Age
- 40 years to 80 years
- People
- 5,250 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06283966 · EU 2023-507407-59-00 - No phaseTaking peopleAn Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients With Severe Emphysema
- Where
- Brescia
- Age
- 40 years to 80 years
- People
- 200 worldwide
- Run by
- Pulmonx Corporation
See details and how to joinNCT06035120 - Phase 3Taking peopleA Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
- Where
- Ferrara, Florence, Montebelluna, Naples, Pavia, Rome, Sassari, Telese Terme, Tradate
- Age
- 40 years to 80 years
- People
- 990 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06883305 · EU 2024-517458-90-00 - Phase 2Taking peopleA study to investigate the effect of AZD6793 in participants with moderate to very severe chronic obstructive pulmonary disease
- Where
- Busto Arsizio, Cuneo, Ferrara, Monza, Naples, Pavia, Rome, Statte, Telese Terme
- Age
- 18 years and over
- People
- 307 worldwide
- Run by
- AstraZeneca AB
See details and how to join2025-520473-40-00 · EU 2025-520473-40-00 - Phase 3Taking peopleeValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
- Where
- Brescia, Ferrara, Naples, Rome, Taranto
- Age
- 40 years to 75 years
- People
- 1,196 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT07177339 · EU 2025-521108-23-00 - No phaseTaking peopleIdentification of Diagnostic and Prognostic Biomarkers in the Pathological Continuum of Bronco Chronic Obstructive Pulmonary Disease, Idiopathic Pulmonary Fibrosis and Pulmonary Neoplasia
- Where
- Milan
- Age
- 18 years and over
- People
- 120
- Run by
- Fondazione Don Carlo Gnocchi ETS
See details and how to joinNCT07707245 - No phaseTaking peopleEffect of Combined Endurance Training on ADL and Walking in COPD Patients
- Where
- Lumezzane, Montescano, Tradate
- People
- 36
- Run by
- Istituti Clinici Scientifici Maugeri SpA
See details and how to joinNCT05708443 - No phaseTaking peopleEffect of Simeox® on Residual Volume in COPD Patients With Pulmonary Hyperinflation
- Where
- Codogno
- Age
- 18 years and over
- People
- 23
- Run by
- Azienda Socio Sanitaria Territoriale di Lodi
See details and how to joinNCT07665931 - No phaseTaking peopleEffects of Oxygen Supplementation During the 6-Minute Walk Test in Chronic Respiratory Failure or Exertional Hypoxemia
- Where
- Bari, Lumezzane, Montescano, Pavia, Taranto, Veruno
- Age
- 18 years and over
- People
- 114
- Run by
- Istituti Clinici Scientifici Maugeri SpA
See details and how to joinNCT07451977 - No phaseTaking peopleThe CATALINA Study
- Where
- Ferrara
- Age
- 18 years and over
- People
- 1,000 worldwide
- Run by
- Wim Janssens
See details and how to joinNCT05008081 - No phaseTaking peopleClinical-ultrasonographic Assessment of Pulmonary Emphysema
- Where
- Acquaviva Delle Fonti, Naples, Rome, Trento
- Age
- 18 years and over
- People
- 1,628
- Run by
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
See details and how to joinNCT06533371 - No phaseTaking peopleUltrasound and Respiratory Physiological Signals in Lung Diseases
- Where
- Rome
- Age
- 18 years and over
- People
- 25
- Run by
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
See details and how to joinNCT06068647 - No phaseNot yet taking people in ItalyEffect on Bronchodilation Response and Ventilation Heterogeneity of Different Inhalation Volumes in COPD
- Where
- Milan
- Age
- 40 years and over
- People
- 30
- Run by
- University of Milan
See details and how to joinNCT05381415 - No phaseEnrolling by invitationThe Italian Registry of Patients With Chronic Obstructive Pulmonary Disease
- Where
- Milan
- Age
- 40 years and over
- People
- 10,000
- Run by
- University of Milan
See details and how to joinNCT06652776 - Phase 4Not yet taking people in ItalyEffect of add-on Doxofylline on Lung Function in Stable COPD
- Where
- Milan
- Age
- 40 years and over
- People
- 78
- Run by
- University of Milan
See details and how to joinNCT04238221 - Phase 4Not yet taking people in ItalyImmuno-inflammatory Response of Erdosteine in COPD
- Where
- Milan
- Age
- 45 years and over
- People
- 30
- Run by
- Pierachille Santus, MD, PhD
See details and how to joinNCT07329946 · EU 2025-524821-42-00